for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AnPac Bio-Medical Science Co Ltd - ADR

ANPC.O

Latest Trade

1.17USD

Change

-0.04(-2.90%)

Volume

89,389

Today's Range

1.16

 - 

1.25

52 Week Range

1.01

 - 

12.09

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.21
Open
1.17
Volume
89,389
3M AVG Volume
6.93
Today's High
1.25
Today's Low
1.16
52 Week High
12.09
52 Week Low
1.01
Shares Out (MIL)
17.77
Market Cap (MIL)
20.81
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q4 2021 AnPac Bio-Medical Science Co Ltd Earnings Release

Latest Developments

More

AnPac Bio And Roche Pharmaceuticals China Entered Into Cooperation

AnPac Bio-Medical Science Co Ltd Pre-Announced It Has Experienced Strong Growth In Test Volume In First Half Year Of 2021

AnPac Bio's First Disease Treatment Patent Granted, Cancer Treatment Project Secured Funds

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AnPac Bio-Medical Science Co Ltd - ADR

AnPac Bio-Medical Science Co., Ltd. is a China-based biotechnology company focused on early cancer screening and detection. The Company markets and sells multi-cancer screening and detection test that uses cancer differentiation analysis (CDA), technology and its cancer-detection device or CDA device. In addition to early cancer screening and detection, its CDA technology assists physicians in cancer diagnosis, prognosis and recurrence. Its CDA technology provides a platform on which it has developed cancer screening and detection test using its CDA technology, or CDA test, and its CDA device. Its CDA technology focuses on biophysical properties in human blood. The Company have established two clinical laboratories in China and one clinical laboratory in the United States.

Industry

Business Services

Contact Info

801 Bixing Street, Bihu County

Lishui, ZHJ

F4 323006

China

+86.578.20516666

http://www.anpac.cn/

Executive Leadership

Chang Yu

Chairman of the Board, Chief Executive Officer, Founder

Herbert Yu

Co-Founder, Chief Medical officer

Jinqiu Tang

Chief Financial Officer

Weidong Dai

President, China

Sunil Pandit

Chief Executive Officer - United States

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Anpac Bio Launches New Immunology Test Product Line

* ANPAC BIO LAUNCHES NEW IMMUNOLOGY TEST PRODUCT LINE Source text for Eikon: Further company coverage:

BRIEF-AnPac Bio-Medical Enters Into 3-Year Cancer Screening Collaboration Contract With Beijing Yuan Jian Health Management

* ANPAC BIO-MEDICAL -ENTERED INTO RECORD, 3-YEAR STRATEGIC CANCER SCREENING COLLABORATION CONTRACT WITH BEIJING YUAN JIAN HEALTH MANAGEMENT Source text for Eikon: Further company coverage:

BRIEF-AnPac Bio Signs A Multi-Million Dollar Contract For Cancer Screening

* ANPAC BIO SIGNS A RECORD MULTI-MILLION DOLLAR CONTRACT FOR CANCER SCREENING

BRIEF-Anpac Bio-Medical Science Co Says Jinqiu Tang Appointed CFO

* ANPAC BIO ANNOUNCES APPOINTMENT OF NEW CHIEF FINANCIAL OFFICER

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up